Barriers to HCV Testing in Drug Treatment Services for People who inject drugs

People who inject drugs (PWID) remain a key risk group for hepatitis C virus infection (HCV) with national prevalence estimates ranging from 13.8% (Malta) to 84.3% (Portugal) in Europe.  To reach the global and European elimination goals, HCV testing and treatment of PWID is required at larger scale. To address this, an initiative to promote HCV testing in drug treatment settings across Europe is being piloted by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).